Indivior Pharmaceuticals, Inc. (INDV) Form 8-K — Aug 3, 2026
Indivior Pharmaceuticals reported strong second-quarter 2026 financial results, with total net revenue increasing 14% year-over-year to $343 million. This growth was primarily driven by a 21% increase in SUBLOCADE net revenue to $253 million, resulting in record GAAP net income of $122 million and adjusted EBITDA of $186 million. Based on this performance, the company raised its full-year 2026 financial guidance, now projecting total net revenue between $1.295 billion and $1.365 billion and adjusted EBITDA between $700 million and $740 million. Indivior also returned significant capital to shareholders, repurchasing approximately 4.7 million shares for $175 million during the quarter.
Key figures
- Eps
- 0.98
- Revenue
- 343
- Net Income
- 122
- Total Debt
- 487
- Cash Position
- 249
- Adjusted EBITDA
- 186
- Sublocade Revenue
- 253
- Guidance EBITDALow
- 700
- Guidance EBITDAHigh
- 740
- Guidance Revenue Low
- 1295
- Guidance Revenue High
- 1365
- Share Repurchase Cost
- 175
- Adjusted EBITDAChange
- +111%
- Ytd Share Repurchase Cost
- 300
Price after filing
Close on the filing date to close N calendar days later (from $40.22). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.